GIANNATEMPO, PATRIZIA
 Distribuzione geografica
Continente #
EU - Europa 980
NA - Nord America 559
AS - Asia 221
SA - Sud America 6
Totale 1.766
Nazione #
US - Stati Uniti d'America 554
DE - Germania 520
GB - Regno Unito 214
CN - Cina 99
IT - Italia 80
SG - Singapore 71
SE - Svezia 62
RU - Federazione Russa 23
IE - Irlanda 21
FI - Finlandia 13
KR - Corea 13
FR - Francia 12
IN - India 11
HK - Hong Kong 10
BE - Belgio 7
JP - Giappone 5
TR - Turchia 5
UA - Ucraina 5
BR - Brasile 4
CA - Canada 4
NL - Olanda 4
DK - Danimarca 3
ID - Indonesia 3
PL - Polonia 3
AT - Austria 2
CZ - Repubblica Ceca 2
ES - Italia 2
GR - Grecia 2
NO - Norvegia 2
PT - Portogallo 2
VN - Vietnam 2
AR - Argentina 1
EC - Ecuador 1
IL - Israele 1
MX - Messico 1
MY - Malesia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 1.766
Città #
Frankfurt am Main 483
Chandler 182
Southend 179
Singapore 41
Seattle 34
Princeton 30
Santa Clara 28
Wilmington 27
Munich 26
Fairfield 25
Milan 25
Dublin 21
Ann Arbor 20
Phoenix 13
Des Moines 12
Houston 11
Nanjing 11
Ashburn 10
Beijing 10
Falls Church 10
Woodbridge 10
Hong Kong 9
Bengaluru 7
Brussels 7
Cambridge 7
Jinan 7
New York 6
Redwood City 6
San Diego 6
Boardman 5
Eitensheim 5
Kent 4
Shanghai 4
Shenyang 4
Tokyo 4
Amsterdam 3
Aprilia 3
Changsha 3
Chicago 3
Fuzhou 3
Kunming 3
Lessolo 3
London 3
Los Angeles 3
Piacenza 3
Seoul 3
Toronto 3
Yubileyny 3
Ancona 2
Angri 2
Brno 2
Buffalo 2
Chengdu 2
Diyarbakir 2
Florence 2
Formia 2
Haikou 2
Hangzhou 2
Hanoi 2
Hefei 2
Helsinki 2
Ipswich 2
Jakarta 2
Jiaxing 2
Molteno 2
Mountain View 2
Mumbai 2
Quanzhou 2
Rome 2
Taranto 2
Villiers-sur-Marne 2
Almere Stad 1
Andover 1
Athens 1
Baltimore 1
Berlin 1
Bitonto 1
Bratislava 1
Brugine 1
Central District 1
Cleveland 1
Concesio 1
Düsseldorf 1
Freitas 1
Fremont 1
Guangzhou 1
Haifa 1
Harrow 1
Hebei 1
Huntington 1
Hyderabad 1
Kuala Lumpur 1
Madrid 1
Medford 1
North Bergen 1
Novara 1
Oslo 1
Ottawa 1
Polska 1
Prata 1
Totale 1.403
Nome #
Corrigendum to “Recommendations for surveillance and follow-up of men with testicular germ cell tumors: A multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica” (Critical Reviews in Oncology / Hematology (2019) 137 (154–164), (S1040842819300587), (10.1016/j.critrevonc.2019.03.006)) 218
Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma 156
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors : implications for clinical practice, trial design, and molecular interrogation 152
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma 146
Quality of life and pain control following laparoscopic retroperitoneal lymph node dissection in early-stage nonseminoma. 138
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy 136
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer 134
Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica 129
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial 111
Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma : a systematic review and meta-analysis of patient outcomes 101
Biomarker-driven immunotherapy for precision medicine in prostate cancer 101
Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes 93
Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment 86
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer : an open label, single-group, phase 2 trial 85
Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer 82
Totale 1.868
Categoria #
all - tutte 5.209
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.209


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202076 0 0 0 0 0 4 7 9 26 18 7 5
2020/2021138 47 8 6 4 22 10 9 14 9 4 1 4
2021/2022203 6 5 8 7 12 16 7 6 10 20 24 82
2022/2023347 45 55 38 54 13 48 7 20 54 2 8 3
2023/2024428 8 6 8 6 42 7 65 60 27 64 67 68
2024/2025319 62 55 52 91 50 9 0 0 0 0 0 0
Totale 1.868